What is the recommended timeframe to stop taking lisinopril (Angiotensin-Converting Enzyme (ACE) inhibitor) before starting losartan (Angiotensin II Receptor Blocker (ARB))?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timeframe to Stop Lisinopril and Start Losartan

When switching from lisinopril (ACE inhibitor) to losartan (ARB), you should wait at least 24 hours between stopping lisinopril and starting losartan to minimize the risk of adverse effects while maintaining blood pressure control.

Rationale for Switching Between ACE Inhibitors and ARBs

  • ACE inhibitors and ARBs are both effective antihypertensive medications that work on the renin-angiotensin-aldosterone system (RAAS), but through different mechanisms 1
  • Common reasons for switching from an ACE inhibitor to an ARB include:
    • ACE inhibitor-induced cough (which does not occur with ARBs) 1
    • Angioedema with ACE inhibitors (ARBs have lower risk) 2
    • Intolerance to other side effects 1

Evidence-Based Switching Protocol

Immediate Switch Approach

  • Research shows that switching directly from an ACE inhibitor to an ARB is generally safe and effective 3
  • In a study of 177 hypertensive patients switching from captopril to losartan, there were no significant adverse events or symptomatic hypotension when switching immediately 3

Standard Recommendation

  • Allow at least 24 hours between stopping lisinopril and starting losartan 4
  • Losartan reaches maximum concentration in 1-2 hours after administration, with a half-life of 6-9 hours for its active metabolite E-3174 4
  • This timeframe allows for adequate clearance of lisinopril while minimizing the period without RAAS blockade 4

Special Considerations

  • For patients switching to sacubitril/valsartan (ARNI): A 36-hour washout period is required between stopping an ACE inhibitor and starting an ARNI due to increased risk of angioedema when these mechanisms overlap 1
  • For patients with history of angioedema with ACE inhibitors: Consider a longer washout period of up to 6 weeks before starting an ARB 2
  • For patients with kidney dysfunction: No dosage adjustment of losartan is necessary for various degrees of renal insufficiency 4

Dosing Considerations

  • Losartan is typically started at 50 mg once daily, which can be administered without regard to meals 4
  • Both once-daily and twice-daily regimens of losartan are effective, with some evidence suggesting twice-daily administration may provide better 24-hour blood pressure control 5
  • Maximum recommended daily dose of losartan is 100 mg 4

Monitoring After Switching

  • Monitor blood pressure within 1-2 weeks after switching to ensure adequate control 1
  • Check serum creatinine and potassium within 1-2 weeks, especially in patients with pre-existing kidney dysfunction 1
  • Some patients may experience an initial increase in creatinine (up to 50% above baseline) which is generally acceptable if stable 1

Potential Pitfalls to Avoid

  • Never use ACE inhibitors and ARBs concurrently: This combination increases risk of adverse effects without additional benefit 1
  • Temporary discontinuation during acute illness: Both ACE inhibitors and ARBs should be temporarily stopped during episodes of volume depletion (vomiting, diarrhea, etc.) to prevent acute kidney injury 1
  • Medication adherence challenges: When switching medications, ensure the patient understands the new dosing schedule to maintain adherence 1

By following these guidelines, you can safely transition patients from lisinopril to losartan while maintaining effective blood pressure control and minimizing the risk of adverse effects.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Risk of Angioedema with Olmesartan

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical pharmacokinetics of losartan.

Clinical pharmacokinetics, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.